Fibrolamellar Cancer

Fibrolamellar Cancer Foundation's official Twitter page. Focused on finding effective treatments for #fibrolamellar carcinoma (a rare form of liver cancer).

[Fibrolamellar Cancer @FibroFoundation]

A landmark study in Nature Medicine shows a novel vaccine can train the immune system to fight fibrolamellar carcinoma—leading to long-term disease control and even complete remission for some patients.
Learn more: https://t.co/DpyYQRdL9K

[Fibrolamellar Cancer @FibroFoundation]

FCF is pleased to announce that it has awarded an research grant to Dr. Hugo Jimenez of Wayne State University to investigate the effectiveness of using low energy electromagnetic fields to treat fibrolamellar carcinoma (FLC).
https://t.co/bu6VV1GkKs

[Fibrolamellar Cancer @FibroFoundation]

FCF is pleased to announce that it is funding a 16-patient extension of a clinical trial at Johns Hopkins. The trial is testing the ability of a FLC-specific vaccine to produce an immune response against the disease.
https://t.co/sknkPHBGmB

[Fibrolamellar Cancer @FibroFoundation]

Marina Baretti, MD of Johns Hopkins University describes recently approved protocol changes to a clinical trial for FLC patients that will allow enrolled patients to self-administer the glutamine antagonist drug (DRP-104) at home.
https://t.co/UKhwSLItQT

[Fibrolamellar Cancer @FibroFoundation]

FCF is pleased to announce that it has awarded a grant to Dr. Juliane Walz of the University Hospital Tübingen for a clinical trial testing a therapeutic peptide vaccine as an adjuvant therapy.
https://t.co/2AuWrxCu4y

[Fibrolamellar Cancer @FibroFoundation]

A FEW MORE SPOTS ARE AVAILABLE......
Registration is now OPEN for the 2024 Patient & Family Gathering in Stowe, Vermont
Sept 13 - Sept 15, 2024
SPACE IS LIMITED
Click on the link below to register.
https://t.co/ZkdlFf2PvI

[Fibrolamellar Cancer @FibroFoundation]

FCF is pleased to announce that it has awarded a grant to Sean Ronnekleiv-Kelly, MD of the University of Wisconsin-Madison School of Medicine to determine if targeting CDK7 could be a useful treatment approach for FLC.

https://t.co/pxcxj33pbL

[Fibrolamellar Cancer @FibroFoundation]

FCF is please to announce that in-person and virtual registration is now open for FCF's second Fibrolamellar Patient & Research Summit to be held on June 9-10, 2024 in Greenwich, Connecticut.

https://t.co/7v1Ua1UYn4

[Fibrolamellar Cancer @FibroFoundation]

Mark Yarchoan, MD and Marina Baretti, MD of Johns Hopkins University discuss the launch of a clinical trial of the glutamine antagonist DRP-104 for fibrolamellar patients.

https://t.co/xCyGv4JAOd

[Fibrolamellar Cancer @FibroFoundation]

FCF is proud to be the recipient of the Ryan Couling Memorial Hockey Tournament Fundraiser.
RCMT donated $8,062.50 to FCF.
We are very grateful to the Couling Family!
To learn more about Ryan, and RCMT, please visit their website:
https://t.co/gGxT3tCeVM...

[Fibrolamellar Cancer @FibroFoundation]

You can play a crucial role in funding groundbreaking research & clinical trials to improve treatment options for FLC patients. Your donations “fund the fight” & move us closer to a future free from FLC. 100% of donations to FCF directly fund research.
https://t.co/URMlXO2iBI

[Fibrolamellar Cancer @FibroFoundation]

FCF is please to announce that it has funded a new multi-institutional study directed by Roshni Dasgupta, MD of the Cincinnati Children’s Hospital (CCHMC) to better understand the incidence and accuracy of diagnosis of FLC.

https://t.co/IznThPFkZf

[Fibrolamellar Cancer @FibroFoundation]

This week, a clinical trial of a peptide vaccine (FusionVAC22) in combination with an immune checkpoint inhibitor (atezolizumab) treated its first patient in Tübingen, Germany.

https://t.co/qxpnyQgGHp

[Fibrolamellar Cancer @FibroFoundation]

FCF is please to announce that it has awarded a grant for additional studies to be conducted by John Scott, PhD of the University of Washington in Seattle.

https://t.co/7BKxQye3Jn

[Fibrolamellar Cancer @FibroFoundation]

Thank you to Stone Point Capital, as well as the sponsors and participants in the 2023 Stone Point Capital Charity Golf Tournament. This years event, held on October 2nd, raised a record amount of funding for the Foundation.

https://t.co/Sb8RlQ2hhq

[Fibrolamellar Cancer @FibroFoundation]

October is Liver Cancer Awareness Month, a chance to raise awareness and funds to improve the detection and treatment of these diseases, plus show support for those who have heard the terrifying words - "you have liver cancer."

https://t.co/RTpuXvfpGd

[Fibrolamellar Cancer @FibroFoundation]

September 30 is Rare Cancer Day! Spearheaded by the NORD's Rare Cancer Coalition, Rare Cancer Day is observed on September 30 each year to highlight the challenges facing rare cancer patients and the need for greater research funding.

https://t.co/c4fUIHsYZt

[Fibrolamellar Cancer @FibroFoundation]

While childhood cancer is rare, it is the leading disease-related cause of death in children and adolescents. In recognition of this issue, September is internationally recognized as "Childhood Cancer Awareness Month".

https://t.co/YNPeZh7ki6

[Fibrolamellar Cancer @FibroFoundation]

FCF is please to announce that it has established a new partnership with the Center for Patient Derived Models (CPDM) at the Dana Farber Cancer Institute in Boston. #DanaFarber

https://t.co/W6bUwXaCNd

[Fibrolamellar Cancer @FibroFoundation]

FCF awards a grant to support a clinical trial of a glutamine antagonist in combination with a checkpoint inhibitor at Johns Hopkins University.

https://t.co/sJAZSqb7e9